Claims
- 1. A compound of formula an N-oxide form, a pharmaceutically acceptable acid addition salt and a stereochemically isomeric form thereof, whereinR1 is C1-6alkyloxy, C2-6alkenyloxy or C2-6alkynyloxy; R2 is hydrogen or C1-6alkyloxy, or when taken together R1 and R2 may form a bivalent radical of formula —O—CH2—O— (a-1), —O—CH2—CH2— (a-2), —O—CH2—CH2—O— (a-3), —O—CH2—CH2—CH2— (a4), —O—CH2—CH2—CH2—O— (a-5), —O—CH2—CH2—CH2—CH2— (a6), wherein in said bivalent radicals one or two hydrogen atoms may be substituted withC1-6alkyl; R3 is hydrogen or halo; L is a radical of formula —Alk—NR5R6 (b-2), wherein Alk is C1-12alkanediyl;R5 is hydrogen or C1-6alkyl; R6 is Het2; Het2 is selected from furan substituted with C1-6alkyl or halo; tetrahydrofuran substituted with C1-6alkyl; dioxolane substituted with C1-6alkyl, dioxane substituted with C1-6alkyl; tetrahydropyran substituted with C1-6alkyl; pyrrolidinyl substituted with one or two substituents each independently selected from halo, hydroxy, cyano, or C1-6alkyl; pyridinyl substituted with one or two substituents each independently selected from halo, hydroxy, cyano, C1-6alkyl; pyrimidinyl substituted with one or two substituents each independently selected from halo, hydroxy, cyano, C1-6alkyl, C1-6alkyloxy, amino and mono and di(C1-6alkyl)amino; pyridazinyl substituted with one or two substituents each independently selected from hydroxy, C1-6alkyloxy, C1-6alkyl or halo; pyrazinyl substituted with one or two substituents each independently selected from halo, hydroxy, cyano, C1-6alkyl, C1-6alkyloxy, amino, mono- and di(C1-6alkyl)amino and C1-6alkyloxycarbonyl; Het2 can also be selected from the radicals of formula wherein R13 and R14 each independently are hydrogen or C1-4alkyl.
- 2. A compound according to claim 1, wherein R1 and R2 are taken together to form a radical of formula (a-2) or (a-3), wherein optionally one or two hydrogen atoms are substituted with methyl.
- 3. A compound according to claim 1, wherein R3 is halo.
- 4. A compound according to claim 2, wherein R3 is chloro.
- 5. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically active amount of a compound as claimed in claim 1.
- 6. A process for preparing a pharmaceutical composition as claimed in claim 5 characterized in that a therapeutically active amount of a compound is intimately mixed with a pharmaceutically acceptable carrier.
- 7. A method for treating conditions related to a hampered or impaired gastrointestinal transit comprising administering to a host in need thereof an effective amount of a compound of formula (I′) as claimed in claim 1.
- 8. A process for preparing a compound of formula (I′), as claimed in claim 1, characterized bya) reacting an intermediate of formula (II) with an carboxylic acid derivative of formula (III) or a reactive functional derivative thereof wherein L, R1, R2 and R3 are as defined in claim 1.
Priority Claims (1)
Number |
Date |
Country |
Kind |
96200525 |
Feb 1996 |
EP |
|
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a continuation application of U.S. Ser. No. 09/933,094, filed Aug. 20, 2001, now U.S. Pat. No. 6,509,339 B2, which application is a continuation application of U.S. Ser. No. 09/125,901, filed Aug. 27, 1998, now U.S. Pat. No. 6,291,481, which application is the national stage of application No. PCT/EP97/00585, filed Feb. 7, 1997.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
5705509 |
Gaster et al. |
Jan 1998 |
A |
Foreign Referenced Citations (10)
Number |
Date |
Country |
WO 9303725 |
Mar 1993 |
WO |
WO 9305038 |
Mar 1993 |
WO |
WO 9316072 |
Aug 1993 |
WO |
WO 9405654 |
Mar 1994 |
WO |
WO 9408994 |
Apr 1994 |
WO |
WO 9408995 |
Apr 1994 |
WO |
WO 9410174 |
May 1994 |
WO |
WO 9429298 |
Dec 1994 |
WO |
WO 9628424 |
Sep 1996 |
WO |
WO 9633186 |
Oct 1996 |
WO |
Non-Patent Literature Citations (3)
Entry |
Bioorg. Med. Chem. Lett., vol. 6, No. 3, pp. 263-266 1996; Fancelli, D. et al., “Serotoninergic-5-HT3 and 5-HT4 Receptor Activities of Dihydrobenzofuren Carboxylic Acid Derivatives”. |
Bioorg. Med. Chem. Lett., vol. 4, No. 20, pp. 2481-2484, 1994; Clark, R.D. et al., “Synthesis and Preliminary Pharmacological Evaluation of 2-Benxyloxy-Substituted Aryl Ketones as 5HT4 Receptor Antagonists”. |
J. Med. Chem. (1993), 36(25), pp. 4121-4123; Gaster, I.M. et al., “(1-Butyl-4-piperidinyl)methyl 8-Amino-7-chloro-1,4-benzodioxane-5-carboxylate Hydrochloride: A Highly Potent and Selective 5-HT4 Receptor Antagonist Derived from Metoclopramide”. |
Continuations (2)
|
Number |
Date |
Country |
Parent |
09/933094 |
Aug 2001 |
US |
Child |
10/299317 |
|
US |
Parent |
09/125901 |
|
US |
Child |
09/933094 |
|
US |